56,932 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Bought by Trexquant Investment LP

Trexquant Investment LP acquired a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 56,932 shares of the biotechnology company’s stock, valued at approximately $5,251,000. Trexquant Investment LP owned 0.09% of Blueprint Medicines at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in BPMC. Bank of New York Mellon Corp raised its stake in Blueprint Medicines by 1.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 266,744 shares of the biotechnology company’s stock worth $13,396,000 after buying an additional 4,127 shares during the period. Allspring Global Investments Holdings LLC raised its stake in shares of Blueprint Medicines by 26.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,137 shares of the biotechnology company’s stock valued at $158,000 after purchasing an additional 653 shares during the period. Teacher Retirement System of Texas raised its stake in shares of Blueprint Medicines by 5.3% in the 3rd quarter. Teacher Retirement System of Texas now owns 17,144 shares of the biotechnology company’s stock valued at $861,000 after purchasing an additional 870 shares during the period. Los Angeles Capital Management LLC raised its stake in shares of Blueprint Medicines by 2.5% in the 3rd quarter. Los Angeles Capital Management LLC now owns 14,493 shares of the biotechnology company’s stock valued at $728,000 after purchasing an additional 355 shares during the period. Finally, Assenagon Asset Management S.A. acquired a new stake in shares of Blueprint Medicines in the 3rd quarter valued at about $469,000.

Blueprint Medicines Stock Performance

Blueprint Medicines stock opened at $102.71 on Thursday. Blueprint Medicines Co. has a 52 week low of $43.89 and a 52 week high of $111.02. The stock has a 50-day simple moving average of $95.32 and a 200 day simple moving average of $85.65. The company has a current ratio of 3.76, a quick ratio of 3.61 and a debt-to-equity ratio of 0.67.

Insider Transactions at Blueprint Medicines

In other news, insider Christopher K. Murray sold 621 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $93.65, for a total transaction of $58,156.65. Following the completion of the sale, the insider now owns 36,374 shares in the company, valued at $3,406,425.10. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, EVP Tracey L. Mccain sold 5,194 shares of Blueprint Medicines stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $90.69, for a total value of $471,043.86. Following the completion of the sale, the executive vice president now directly owns 60,498 shares in the company, valued at $5,486,563.62. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Christopher K. Murray sold 621 shares of Blueprint Medicines stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $93.65, for a total transaction of $58,156.65. Following the completion of the sale, the insider now owns 36,374 shares of the company’s stock, valued at $3,406,425.10. The disclosure for this sale can be found here. Insiders sold a total of 104,123 shares of company stock worth $9,554,679 over the last quarter. Company insiders own 3.88% of the company’s stock.

Analysts Set New Price Targets

BPMC has been the topic of several recent research reports. JMP Securities lifted their price target on Blueprint Medicines from $114.00 to $125.00 and gave the company a “market outperform” rating in a research note on Friday, May 3rd. Wedbush reissued an “outperform” rating and issued a $110.00 price target on shares of Blueprint Medicines in a research note on Friday, April 26th. Stifel Nicolaus lifted their price target on Blueprint Medicines from $120.00 to $130.00 and gave the company a “buy” rating in a research note on Friday, April 26th. The Goldman Sachs Group raised their price objective on Blueprint Medicines from $121.00 to $168.00 and gave the company a “buy” rating in a report on Monday, May 6th. Finally, Barclays raised their price objective on Blueprint Medicines from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Friday, May 3rd. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $102.65.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.